PepTivator® CMV pp65

PepTivator® CMV pp65 is a peptide pool that consists mainly of 15-mer peptides with 11–amino acid (aa) overlap, covering the complete sequence of the pp65 protein of cytomegalovirus (UniProt ID: P06725).

PepTivator peptide pools have been developed for the efficient in vitro stimulation of antigen-specific CD4+ and CD8+ T cells, as peptides of 15–aa length with 11–aa overlap represent an optimized solution for stimulating both CD4+ and CD8+ T cells in various applications.

Quantitative, phenotypical, or functional ana

... read more
Choose your product:

Related products for PepTivator® CMV pp65

Specifications for PepTivator® CMV pp65
Overview

PepTivator® CMV pp65 is a peptide pool that consists mainly of 15-mer peptides with 11–amino acid (aa) overlap, covering the complete sequence of the pp65 protein of cytomegalovirus (UniProt ID: P06725).

PepTivator peptide pools have been developed for the efficient in vitro stimulation of antigen-specific CD4+ and CD8+ T cells, as peptides of 15–aa length with 11–aa overlap represent an optimized solution for stimulating both CD4+ and CD8+ T cells in various applications.

Quantitative, phenotypical, or functional analysis of pp65-specific T cell immunity can provide important information on the natural course of immune responses in healthy or immunocompromised individuals.

Detailed product information
Background information

CMV pp65 (65 kDa lower matrix phosphoprotein), also known as glycoprotein 64 or UL83, is a virion tegument protein and the main component of the enveloped subviral particle. CMV pp65 is an immunodominant target of CD4+ and CD8+ T cell responses to CMV. CMV pp65-specific T cells predominantly produce inflammatory cytokines, such as IFN-γ, IL-2, and TNF-α.

Downstream applications

The in vitro stimulation of pp65-specific CD4+ and CD8+ T cells with PepTivator CMV pp65 causes the secretion of effector cytokines and the upregulation of activation markers, which then allow the detection and isolation of pp65-specific T cells 1-6:

  • Detection and analysis of CMV pp65-specific CD4+ and CD8+ effector/memory T cells in PBMCs by MACS® Cytokine Secretion Assays, intracellular staining, or other technologies.
  • Isolation of viable CMV pp65-specific CD4+ T cells with the CD154 MicroBead Kit, or of CD4+ and CD8+ T cells using the CD137 MicroBead Kit or MACS Cytokine Secretion Assay - Cell Enrichment and Detection Kits. Subsequently, cells can be expanded for generation of T cell lines.
  • Generation of CMV pp65-specific CD4+ and CD8+ effector/memory T cells from naive T cell populations.
  • Pulsing of antigen-presenting cells for research on dendritic cell vaccination.
Product data and images for PepTivator® CMV pp65
Figure 1

Production of IFN-γ by human CD4+ or CD8+ T cells after stimulation with different antigens using PepTivator Peptide Pools. Data from two different donors are shown (triplicates).

Citations for PepTivator® CMV pp65
Publications
  1. Dodero, A. et al. (2009) Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood 113: 4771-4779
  2. Peggs, K. S. et al. (2011) Directly selected cytomegalovirus-reactive donor T cells confer rapid and safe systemic reconstitution of virus-specific immunity following stem cell transplantation. Clin. Infect. Dis. 52 (1): 49-57
  3. Beck, B. et al. (2011) Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J. Transl. Med. 9: 151
  4. Aïssi-Rothé, L. et al. (2010) Rapid generation of full clinical-grade human antiadenovirus cytotoxic T cells for adoptive immunotherapy. J Immunother 33 (4): 414-424
  5. Faist, B. et al. (2010) Cytomegalovirus infection- and age-dependent changes in human CD8+ T-cell cytokine expression patterns. Clin. Vaccine Immunol. 17 (6): 986-992
  6. Zandvliet, M. et al. (2010) Co-ordinated isolation of CD8(+) and CD4(+) T cells recognizing a broad repertoire of cytomegalovirus pp65 and IE1 epitopes for highly specific adoptive immunotherapy. Cytotherapy 12: 933-944